India’s drug patent policy has been slammed by US companies who are insisting that action be taken in order to improve trade relations.
A federal judge has denied AstraZeneca’s motions to dismiss claims challenging its pay-for-delay deals with three generic pharmaceutical companies in connection to heartburn drug Nexium.
A US company which provides secure personal medical records online has filed a patent infringement case against a rival health-care company.
The government in South Africa is considering changing its national policy on IP, a move that could have far reaching effects for its patents system.
A Japanese research institution has collaborated with three Indian organisations to launch two new virtual centres for scientists and students.
The US District Court for the District of New Jersey has found in favour of Teva Pharmaceutical Industries Ltd in its patent infringement case with Mylan over Parkinson’s disease drug Azilect.
Drug company Watson Laboratories (Actavis) has notified rival Ranbaxy Laboratories that it has applied to sell a generic version of anti-acne product Absorica in the US.
Medical device makers Boston Scientific and OrbusNeich announced on September 17 that they have settled all stent-related patent litigations.
Eli Lilly has filed a NOA against the Canadian government, alleging recent decisions that invalidated patents covering its Zyprexa and Strattera drugs were in breach of NAFTA.
The Indian government has awarded more than two thirds of its recent pharmaceutical patents to foreign drug makers, according to data released by the Indian Patent Office.